$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of.
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of.
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of.
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M